구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Triamcinolone Acetonide |
Overview Company | Wei-Che Ko |
Overview Modality | ANTIBODY |
Overview Target | Diabetic Macular Edema |
Overview Indication | Skin Inflammation; Allergic Contact Dermatitis |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting of STING-TBK1 signaling |
MoA Biomarker | biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Corticosteroids for the treatment of diabetic macular edema with massive hard exudates: An evidence-based update.. Diabetic macular edema (DME) often presents with scattered punctate or massive hard exudates (HE), which can lead to visual acuity impairment. Plaque-like HE, a special type of massive HE, are even an independent risk factor for subfoveal fibrosis. Therefore, the elimination of HE is … |
Clinical Safety signal | Corticosteroids for the treatment of diabetic macular edema with massive hard exudates: An evidence-based update.. Diabetic macular edema (DME) often presents with scattered punctate or massive hard exudates (HE), which can lead to visual acuity impairment. Plaque-like HE, a special type of massive HE, are even an independent risk factor for subfoveal fibrosis. Therefore, the elimination of HE is … |
Clinical Selected reported efficacy | 9.6% |
Clinical Result source | ClinicalTrials.gov NCT00588354 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00588354 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Triamcinolone Acetonide |
Overview Company | Wei-Che Ko |
Overview Modality | ANTIBODY |
Overview Target | Diabetic Macular Edema |
Overview Indication | Skin Inflammation; Allergic Contact Dermatitis |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting of STING-TBK1 signaling |
MoA Biomarker | biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Corticosteroids for the treatment of diabetic macular edema with massive hard exudates: An evidence-based update.. Diabetic macular edema (DME) often presents with scattered punctate or massive hard exudates (HE), which can lead to visual acuity impairment. Plaque-like HE, a special type of massive HE, are even an independent risk factor for subfoveal fibrosis. Therefore, the elimination of HE is … |
Clinical Safety signal | Corticosteroids for the treatment of diabetic macular edema with massive hard exudates: An evidence-based update.. Diabetic macular edema (DME) often presents with scattered punctate or massive hard exudates (HE), which can lead to visual acuity impairment. Plaque-like HE, a special type of massive HE, are even an independent risk factor for subfoveal fibrosis. Therefore, the elimination of HE is … |
Clinical Selected reported efficacy | 9.6% |
Clinical Result source | ClinicalTrials.gov NCT00588354 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00588354 |
추천 비교
추천 비교